Ind-Swift Laboratories Limited has presented its investor presentation for the un-audited financial results for the quarter ended December 31, 2025. The company reported stable revenue for Q3 FY26, with a 6.60% increase in Operating EBITDA and a 48 BPS expansion in Operating EBITDA margin, driven by reduced raw material and employee benefit expenses. Net Profit (PAT) saw a 22.60% rise quarter-over-quarter. A significant strategic move includes the ₹1,650 Cr divestment of the API & CRAMS business to Synthimed Labs, making Ind-Swift Laboratories a Net Debt Free entity. This divestment, combined with the merger of Ind-Swift Limited into ISLL, has repositioned the company as a Pure-Play Formulations Platform with a revenue base of ₹550 Cr, primarily from exports. The company is focusing on high-growth engines, including strengthening its CDMO visibility through a FY27 accretive Viatris partnership and expanding its Own-Brand footprint in UAE and Central Asia with over 400 registered products. With high-margin segments like Ethical (76% GM), Own-Brand (51% GM), and CMO (42% GM), Ind-Swift Laboratories targets to double its revenue by FY29 while ensuring consistent profitability. The presentation also detailed the company's strategic evolution, growth milestones, transaction summary of the API & CRAMS divestment, and a post-transformation overview highlighting its new operating model with domestic and global business units. The company has a strong R&D focus, with over 1915 dossiers filed and 520+ global approvals. Future regulatory targets include inspections for Saudi FDA and Taiwan FDA in 2025. Financial highlights for Q3 FY26 show Total Revenue at ₹177.06 Cr, Operating EBITDA at ₹9.11 Cr with a 5.95% margin, and PAT at ₹10.74 Cr with a 6.07% margin. For the 9 months ended FY26, Total Revenue was ₹507.93 Cr, Operating EBITDA was ₹26.09 Cr (5.63% margin), and PAT was ₹27.62 Cr (5.44% margin). The company projects a topline CAGR of 20-25%, scaling from ₹550 Cr to ₹1,200+ Cr by FY29. CDMO revenue is expected to triple over four years, and EBITDA margins are projected to expand by 250-300 BPS. Key strategic growth triggers include the Viatris commercialization in FY27, expected to bring ₹200-220 Cr in incremental revenue, and greenfield expansion in UAE, Uzbekistan, and West Africa.
